Informing policy for the Australian context - Costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 50, Issue 1, 2010, Pages 51-59

  Maxwell, Susannah ^a   Brameld, Kate ^a,b,c   Youngs, Leanne ^a   Geelhoed, Elizabeth ^b   O'Leary, Peter ^a,c,d  

^a DEPARTMENT OF HEALTH   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cost effectiveness; Cystic fibrosis; Genetic screening; Prenatal diagnosis; Public policy

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ARTICLE; AUSTRALIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; COST; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERINATAL CARE; PHYSIOTHERAPY; PREGNANCY; PRENATAL SCREENING; PRIORITY JOURNAL; PUBLIC HEALTH; SENSITIVITY ANALYSIS; VITAMIN SUPPLEMENTATION;

AUSTRALIA; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; DECISION TREES; FEMALE; HEALTH CARE COSTS; HEALTH POLICY; HETEROZYGOTE DETECTION; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 77049102412     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2009.01111.x     Document Type: Article

References (53)

1. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007 (Mar 1 29 (3 522 526.
2. Wald NJ, Morris JK, Rodeck CH, Haddow JE, Palomaki GE. Cystic fibrosis: selecting the prenatal screening strategy of choice. Prenat Diagn 2003 23 : 474 483.
3. David TJ. Family life and the daily cystic fibrosis routine. J R Soc Med 2003 96 (7 317.
4. Massie J, Forbes R, duSart D, Bankier A, Delatycki MB. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis. J Paediatr Child Health 2007 43 (11 721 723.
5. Australian Bureau of Statistics. 3301.0 - Births, Australia 2007. Canberra : Australian Bureau of Statistics, 2008.
6. Massie RJ, Delatycki MB, Bankier A. Screening couples for cystic fibrosis carrier status: why are we waiting? Med J Aust 2005 183 (10 501 502.
7. Weijers-Poppelaars FAM, Wildhagen MF, Henneman L, Cornel MC, ten Kate LP. Preconception cystic fibrosis carrier screening: costs and consequences. Genet Test 2005 9 (2 158.
8. Colvin L, Payne J, Parsons D, Kurinczuk JJ, Bower C. Alcohol consumption during pregnancy in nonindigenous West Australian women. Alcohol Clin Exp Res 2007 31 : 276 284.
9. Bellis G, Cazes M, Parant A et al. Cystic fibrosis mortality trends in France. J Cyst Fibros 2007 6 (3 179 186.
10. Sawyer SM, Cerritelli B, Carter LS, Cooke M, Glazner JA, Massie J. Changing their minds with time: a comparison of hypothetical and actual reproductive behaviors in parents of children with cystic fibrosis. Pediatrics 2006 118 : e649 e656.
11. American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics. Update on carrier screening for cystic fibrosis. Obstet Gynecol 2005 (Dec 106 (6 1465 1468.
12. Godard B, ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 2003 11 (Suppl 2 S49 S87.
13. National Health Service UK. National Screening Committee Policy - Cystic Fibrosis Screening (in Pregnancy), 2006. [Accessed February 2009.] Available from URL: http://www.library.nhs.uk/screening/viewResource.aspx?mr= 10&offset=10&catID=1328&resID=35569.
14. Comité Consultatif National d'Éthique pour les sciences de la vie et de la santé (National Consultative Ethics Committee for Health and Life Sciences). OPINION N°83 Generalised prenatal screening for cystic fibrosis Paris : National Consultative Ethics Committee for Health and Life Sciences, 2004.
15. Society of Obstetricians and Gynaecologists Canada (SOGC) Committee Opinion. Cystic fibrosis carrier testing in pregnancy in Canada. J Obstet Gynaecol Can 2002 24 (8 644 647.
16. Burke W, Atkins D, Gwinn M et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002 (Aug 15) 156 (4 311 318.
17. Gudgeon JM, McClain MR, Palomaki GE, Williams MS. Rapid ACCE: e perience with a rapid and structured approach for evaluating gene-based testing. Genet Med 2007 9 : 473 478.
18. Haddow J, Palomaki G. ACCE: a model process for evaluating data on emerging genetic tests. In : Khoury M, Little J, Burke W, eds. Human Genome Epidemiology. Oxford : Oxford University Press, 2004 217 233.
19. Brice P, Jarrett J, Mugford M. Genetic screening for cystic fibrosis: an overview of the science and the economics. J Cyst Fibros 2007 6 (4 255 261.
20. Radhakrishnan M, van Gool K, Hall J, Delatycki MB, Massie J. Economic evaluation of cystic fibrosis screening: a review of the literature. Health Policy 2008 85 : 133 147.
21. Warren E, Anderson R, Proos A, Burnett L, Barlow-Stewart K, Hall J. Cost-effectiveness of a school based Tay-Sachs and cystic fibrosis genetic carrier screening program. Genet Med 2005 7 (7 484 494.
22. Australian Bureau of Statistics. Population Projections Australia: 1999 to 2101. Canberra Australian Bureau of Statistics, 2000.
23. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. Br Med J 2000 320 (7251 1708 1712.
24. Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Best Pract Res Clin Obstet Gynaecol 2000 14 (5 839 854.
25. Tong S, Kaur A, Walker SP, Bryant V, Onwude JL, Permezel M. Miscarriage risk for asymptomatic women after a normal first-trimester prenatal visit. Obstet Gynecol 2008 111 : 710 714.
26. O'Leary P, Breheny N, Reid G, Charles T, Emery J. Regional variations in prenatal screening across Australia: stepping towards a national policy framework. Aust N Z J Obstet Gynaecol 2006 46 (5 427 432.
27. Collins VR, Muggli EE, Riley M, Palma S, Halliday JL. Is Down syndrome a disappearing birth defect? J Pediatr 2008 152 ( 20 24.
28. Scotet V, Duguépéroux I, Audrézet MP et al. Prenatal diagnosis of cystic fibrosis: the 18-year experience of Brittany (western France). Prenat Diagn 2008 28 (3 197 202.
29. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London : National Institute for Health and Clinical Excellence, 2008.
30. Department of Health SA. Cystic Fibrosis Services in South Australia: A Review of Current Service Arrangements and Recommendations for Future Developments. Adelaide : Government of South Australia, 2006.
31. Australian Institute of Health and Welfare. Health Expenditure Australia 2006-07. Canberra : AIHW, 2008.
32. Baumann U, Stocklossa C, Greiner W, Graf von der Schulenburg J, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003 2 : 84 90.
33. Horvais V, Touzet S, Francois S et al. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Int J Technol Assess Health Care 2006 22 (4 525 531.
34. Huot L, Durieu I, Bourdy S et al. Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J Cyst Fibros 2008 7 (5 403 408.
35. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organisation. Pediatrics 1999 103 (6 1273.
36. Nielsen R, Gyrd-Hansen D. Prenatal screening for cystic fibrosis: an economic analysis. Health Econ 2002 11 : 285 299.
37. Sims EJ, Mugford M, Clark A et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007 369 (9568 1187 1195.
38. Johnson JA, Connolly MA, Jacobs P, Montgomery M, Brown N, Zuberbuhler P. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacoeconomics 1999 19 (10 1159 1166.
39. Metz MP, Ranieri E, Gerace RL, Priest KR, Luke CG, Chan A. Newborn screening in South Australia: is it universal? Med J Aust 2003 179 : 412 415.
40. Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS. Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol Assess 2004 8 (33 1 124.
41. Murray A, Clarke A. The ethics of population screening. Curr Paediatr 2002 12 : 447 452.
42. Medical Services Advisory Committee. Nuchal Translucency Measurement in the First Trimester of Pregnancy for the Screening of Trisomy 21 and Other Autosomal Trisomies. Canberra : Commonwealth of Australia, 2002.
43. Rosenberg MA, Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. J Pediatr 2005 147 (3 Suppl 1 S101 S105.
44. Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003 21 (14 1001 1024.
45. Schreyogg J, Hollmeyer H, Bluemel M, Staab D, Busse R. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006 24 (10 999 1009.
46. Cuckle H. Extending antenatal screening in the UK to include common monogenic disorders. Community Genet 2001 4 : 84 86.
47. Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. Br Med J 1995 311 : 1460.
48. Chen L-S, Goodson P. Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: a theory-guided systematic review. Genet Med 2007 9 (7 442 450.
49. Hartley NE, Scotcher D, Harris H et al. The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 1997 (Jun 1) 34 (6 459 464.
50. Rowley P, Loader S, Kaplan R. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Med Genet 1998 63 : 1160 1174.
51. Slostad J, Stein QP, Flanagan JD, Hansen KA. Screening for mutations in the cystic fibrosis transmembrane regulator gene in an infertility clinic. Fertil Steril 2007 88 (6 1687 1688.
52. Watson MS, Cutting GR, Desnick RJ et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel [policy statement]. Genet Med 2004 (Sept/Oct 6 (5 387 391.
53. Delvaux I, Van Tongerloo A, Messiaen L et al. Carrier screening for cystic fibrosis in a prenatal setting [Summary]. Genet Test 2001 5 (2 117 125.